Vertex Pharmaceuticals Incorporated
CorpDigest
Vertex Pharmaceuticals Incorporated
Company History
Founded 1989 in Boston, Massachusetts
Last reviewed: 2026-06-08 · By Swet Parvadiya
Vertex Pharmaceuticals Incorporated generated $10.67 billion in FY2024 net product revenue, operating as the undisputed global monopoly in cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator therapies that commands an 89% gross margin by focusing exclusively on high-margin patented therapeutics. The company's strategic identity was defined through a series of targeted scientific breakthroughs, most notably the development of Trikafta, a triple-combination therapy that generated $9.5 billion in FY2024 sales, representing 89% of total corporate revenue. This pivot has resulted in a highly concentrated portfolio where growth is now being driven by the rapid scaling of next-generation assets, including the CRISPR-Cas9 gene-edited therapy Casgevy and the first-in-class NaV1.8 inhibitor suzetrigine (VX-548) for acute pain. With approximately 5,500 employees and a market capitalization of $115 billion, Vertex allocates $3.1 billion annually to R&D, funding a pipeline of over 40 clinical projects and enabling aggressive acquisitions like the $4.9 billion purchase of Alpine Immune Sciences. The company's future depends on its ability to execute a 10-12% constant currency sales CAGR through 2030, a target that requires the successful commercial launch of its pain and diabetes pipelines and the continuous expansion of its dominant position in CF and gene therapy to offset the impending patent cliffs of its core franchises.
Dr. Joshua Boger is an American scientist and entrepreneur who founded Vertex Pharmaceuticals in 1989 and served as its CEO until 1999. He played a pivotal role in the company's early survival, navigating the severe cash crunch of the mid-1990s and executing the strategic pivot to cystic fibrosis that saved the company from bankruptcy. Boger's background as a research scientist at Merck gave him a unique perspective on the pharmaceutical industry, driving his focus on developing therapies for serious diseases using rational, structure-based drug design. During his tenure, he oversaw the early development of the company's HIV protease inhibitor programs and laid the foundational scientific infrastructure that would eventually lead to the discovery of the CFTR modulators. After stepping down as CEO, Boger remained active in the biotechnology community, serving on the boards of several major pharmaceutical companies and continuing to invest in early-stage life science startups. He is widely respected in the industry for his role in creating a global biopharmaceutical powerhouse and for his commitment to bringing novel, life-saving therapies to patients with limited treatment options.
Dr. Joshua Boger founded Vertex Pharmaceuticals in Cambridge, Massachusetts, with an initial focus on applying structure-based drug design to discover novel therapeutics.
Vertex Pharmaceuticals executed its IPO, raising capital to continue operations and advance its early-stage pipeline programs after facing a severe cash crunch.
Vertex entered into a landmark partnership with the Cystic Fibrosis Foundation, betting the company's future on the hypothesis that small molecules could correct the misfolded CFTR protein.
The FDA approved Kalydeco (ivacaftor), the first CFTR potentiator, marking the beginning of Vertex's ascent to the top of the global rare disease hierarchy.
Vertex received FDA approval for Orkambi, the first CFTR modulator combination therapy for patients with the F508del mutation, the most common cause of cystic fibrosis.
The FDA approved Trikafta (elexacaftor/tezacaftor/ivacaftor), a triple-combination therapy that transformed the treatment paradigm for 90% of the CF population.
Vertex acquired ViaCyte for $320 million, securing foundational stem cell technology for the VX-880 type 1 diabetes program.
The FDA approved Casgevy (exa-cel), the first CRISPR-Cas9 gene-edited therapy, co-developed with CRISPR Therapeutics, for sickle cell disease and transfusion-dependent beta thalassemia.
Vertex acquired Alpine Immune Sciences for $4.9 billion, securing the proprietary PTP115 asset for APOL1-mediated kidney disease.
Vertex reported $10.67 billion in net product revenue for FY2024, with operating income reaching $4.6 billion and free cash flow at $3.5 billion, demonstrating strong performance and robust pipeline execution.
Vertex acquired Alpine Immune Sciences for $4.9 billion to gain control of the proprietary PTP115 asset, an oral inhibitor of APOL1 for the treatment of APOL1-mediated kidney disease.
Vertex acquired ViaCyte for $320 million to secure foundational stem cell technology for the VX-880 investigational stem cell-derived islet cell replacement therapy for type 1 diabetes.
Vertex acquired Semma Therapeutics for $950 million to gain control of its stem cell-derived islet cell technology for the treatment of type 1 diabetes.